Tirzepatide climbs in 2.5 mg increments, from 2.5 mg once weekly to a ceiling of 15 mg. That gives six rungs, and the useful thing to know before reading a price on the tirzepatide board is that only three of them are approved places to stay. The other three exist because the ladder has to be climbed one increment at a time.
2.5 mg is not a dose you are meant to stay on
The Zepbound label starts every indication at 2.5 mg subcutaneously once weekly for four weeks, and then states plainly that the amount is for treatment initiation and is not approved as a maintenance dosage. Mounjaro opens at the same figure and moves up whenever more glycemic control is needed.
That sentence in the label is worth more than it looks. It means a plan that holds a buyer at 2.5 mg indefinitely is not dispensing a reduced version of an approved regimen; it is dispensing a rung the label describes as a starting point. Whether that is reasonable is a clinical question, and what the low-dose evidence covers is the honest answer to it.
5, 10 and 15 mg are the destinations
For weight reduction and long-term maintenance, the recommended maintenance dosage is 5 mg, 10 mg or 15 mg once weekly, and 15 mg is the maximum for every approved indication. Obstructive sleep apnea narrows the list further: there the maintenance dosage is 10 mg or 15 mg, so the lowest maintenance rung is not on the menu for that indication at all.
The pivotal obesity trial used the same three figures. SURMOUNT-1 ran once-weekly tirzepatide at 5 mg, 10 mg and 15 mg against placebo in adults with obesity, each dose held as its own randomized arm for 72 weeks.[1] The sizes of those results belong to the weight-result article; what matters on this page is which numbers were on the card.
The diabetes trial repeats the pattern on its own endpoint. SURPASS-2 assigned 1,879 adults with type 2 diabetes to tirzepatide at 5, 10 or 15 mg or to semaglutide 1 mg for 40 weeks. Estimated mean change in glycated hemoglobin was −2.01, −2.24 and −2.30 percentage points across the three tirzepatide doses.[2] Each step up did a little more, and the gap between the top two rungs was 0.06 points.
Read down that column and the shape of the ladder shows. On this endpoint, most of the change had arrived by the lowest maintenance rung, and each further step added less than the step before it. That is a reason to treat 5 mg as a genuine destination rather than a rung somebody failed to climb past, and it applies to a bill as much as to a chart.
7.5 and 12.5 mg are steps nobody randomized
Those two figures appear in no maintenance list on either label. They exist because escalation moves in 2.5 mg increments with at least four weeks at the current dose. Anyone traveling from 5 mg to 10 mg therefore passes through 7.5 mg, and anyone going from 10 to 15 passes through 12.5.
No arm of SURMOUNT-1 or SURPASS-2 was assigned to either.[1][2] That does not make them unsafe or improper, and a prescriber holding someone at 7.5 mg because 10 was intolerable is making an ordinary clinical judgment. It does mean the published effect sizes have nothing to say about those two rungs specifically, and a seller advertising a price at 12.5 mg is pricing a step rather than a studied destination.
The climb has a floor of twenty weeks
Five increments separate 2.5 mg from 15 mg, and the label requires at least four weeks at each dose before the next increase. That arithmetic sets a minimum of twenty weeks to the ceiling, and the label adds that a maintenance dose someone cannot tolerate is a reason to consider a lower one rather than to push through.
Nothing obliges anyone to reach the top. Someone who does well at 5 mg has arrived at an approved maintenance dosage in four weeks, not twenty. What that means for a bill, and for a plan whose price moves with the dose, is the subject of the titration article.
Two brands, one molecule, different ceilings
Mounjaro and Zepbound are the same active ingredient with different approved uses, and their dose rules diverge at the edges. Mounjaro caps adults at 15 mg once weekly and pediatric patients at 10 mg. Zepbound caps every indication at 15 mg and, for sleep apnea, starts its maintenance range at 10.
A compounded preparation carries none of those boundaries with it. It is prepared to a prescription, so the ladder it follows is the one the prescriber writes, which may or may not match either label. The regulatory distance between those two situations is laid out in the compounding article, and what the container itself holds is covered in what a compounded vial holds.
What to ask before the first charge
Nothing requires a compounded seller to stock all six strengths, and plenty do not. Four questions settle what a plan is really offering, and each has a checkable answer. Which of the six strengths does it actually supply? Is the quoted price attached to a milligram figure or to a volume drawn from a vial of stated concentration? Does that price change at each increment, or do sellers holding one price apply? And what happens if the answer at month six is that 7.5 mg suits you better than 10?
Sellers vary widely in how much of that they publish, and the variation is itself a signal. The individual seller write-ups record what each company states about strengths and dose pricing. The ladder is fixed and public; what changes from one plan to the next is how much of it you are actually being sold.